COVID-19
First uses are envisioned as treatments for severely ill coronavirus patients and individuals at high risk of contracting the disease, including healthcare professionals.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2020.
Abbott’s new point-of-care test for the novel coronavirus that causes COVID-19 was approved by the U.S. Food and Drug Administration (FDA) under Emergency Use Authorization (EUA).
The World Health Organization is launching a clinical trial in Norway and Spain to assess four of the most promising drugs in the fight against COVID-19, the disease caused by the novel coronavirus that has spread across the globe.
The COVID-19 pandemic isn’t likely to end soon. Instead, the crisis stage may continue for weeks or even months before business regains some semblance of normality. The good news is that while biotech companies have slowed their hiring initiatives, layoffs remain unlikely at this point. Instead, biotech companies are enhancing flexibility on nearly every front.
One of the key takeaways from BIO-Europe Spring 2020 was that there is a keen need for greater collaboration and communications among the biotech community, government, non-governmental organizations and the public.
As COVID-19 continues to expand across the globe, more pharmaceutical companies are hitting the brakes on clinical trials as part of an effort to ease the burden on doctors and facilities needed to treat patients combating the disease.
A summary of daily biopharma industry news. Please check out stories that are trending on March 27, 2020.
Sanofi Pasteur and Translate Bio have partnered to develop a novel messenger RNA vaccine for COVID-19, the disease caused by the novel coronavirus.
A summary of daily biopharma industry news. Please check out stories that are trending on March 26, 2020.
PRESS RELEASES